Cegedim Sa · EURONEXT:ALCGM
Cegedim Sa — Investor Day (January 2013)
112 slides from Cegedim Sa's investor day presentation, Jan 22, 2013
Slide 1: 3rd Annual Investor Summit
3rd Annual Investor Summit January 22", 2013 Boulogne-Billancourt
Slide 2: Forward-looking statements
This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward- looking statements involve risk and uncertainty. Forward-looking g statements represent p the company's judgment reg
Slide 3: Agenda
9 1 – 2012 Highlights 9 2 – MI Touch on Windows 8 9 3 – Docnet 9 4 – Cegedim Rx 9 5 – Patient Portal 9 6 – Cegedim Insurance 9 7 – Keep in Touch
Slide 4: 2012 Highlights
2012 Highlights H M. Jan Eryk Um miastowski (Cegedim)
Slide 5: This document should not be distributed with hout Cegedim authorization – Copyright 2013
This document should not be distributed with hout Cegedim authorization – Copyright 2013 5
Slide 6: History of Cegedim
History of Cegedim This document should not be distributed with hout Cegedim authorization – Copyright 2013 6
Slide 7: Cegedim offers a Comprehensive Set of Solutions
Cegedim offers a Comprehennsive Set of Solutions This document should not be distributed with hout Cegedim authorization – Copyright 2013 7
Slide 8: A Unique Presence in the Healthcare Industry
A Unique Presence in the Heaalthcare Industry This document should not be distributed with hout Cegedim authorization – Copyright 2013 8
Slide 9: Leading Positions in Attractive Niche Markets
Leading Positions in Attractivve Niche Markets This document should not be distributed with hout Cegedim authorization – Copyright 2013 9
Slide 10: Competitive Strengths
2 3 Competitive Strengths 1 6 4 5 9 Leading market positions in each off our divisions 9 High g barriers to entry y 9 Strong customer base with recurrin ng revenue 9 Portfolio of innovative and integrate ed products and services 9 Shareholder support 9 Strong and experienced senior man nagement te
Slide 11: The Changing World of the Healthcare
The Changing World of the Healthcare H This document should not be distributed with hout Cegedim authorization – Copyright 2013 11
Slide 12: New Challenges and market Opportunities
New Challenges and market Opportunities This document should not be distributed with hout Cegedim authorization – Copyright 2013 12
Slide 13: Life Sciences Cie Challenges (1/2)
Life Sciences Cie Challenges (1/2) This document should not be distributed with hout Cegedim authorization – Copyright 2013 13
Slide 14: Pipelines Improvement (1/2)
1- Pipelines Improvement (1/2) 9 In the last 2 y years there has been a slig g ght uptick p in new approvals pp by y the FDA and other regulatory authorities, since the slow years of 2005-2010 and acceleration in phase III pipeline news flow since 2010 2012 sales potential of projects with posit
Slide 15: Pipelines Improvement (2/2)
1- Pipelines Improvement (2/2) 9 The p pipeline p of new molecular entities in late-stage g development p suggests gg they y can match lost sales from patent expiriies with futures sales growth, if these projects gain regulatory approval This document should not be distributed with hout Cegedim au
Slide 16: Generic Conversions
2- Generic Conversions 9 Patent cliffs resulting g from recent block kbuster drug g patent p expires p 9 High-barrier products High-barrier High barrier products like topical (creams/pa atches) injectables, atches), injectables respiratory products, products biosimilars, controlled-release produ
Slide 17: Emerging Countries
3- Emerging Countries 9 Key Drivers Favorable demographics Ascension of global middle class Aging population Government support for expanding insuranc ce coverage Rising disposable income 9 Main Market China, Brazil and Russia 9 Cegedim 14% of CRM & Strategic Data revenues, revenues
Slide 18: Life Sciences Cie Challenges (2/2)
Life Sciences Cie Challenges (2/2) This document should not be distributed with hout Cegedim authorization – Copyright 2013 18
Slide 19: Solutions Platform for Life Sciences Cie
Solutions Platform for Life Scciences Cie This document should not be distributed with hout Cegedim authorization – Copyright 2013 19
Slide 20: Market leader Confirmation from Analysts
Market leader Confirmation from f Analysts 2012 2011 Cool Vendors Pharma SFA CRM y Mobility Pharma SFA gg Spend Agg p Report – Vendor Report Technology I Innovation Market Scape Outsourcing Digital Profile Value Matrix Rating + Agg gg Spend p Market Share This document should not be distributed wi
Slide 21: Healthcare Professionals Challenges
Healthcare Professionals Challenges This document should not be distributed with hout Cegedim authorization – Copyright 2013 21
Slide 22: Solutions Platform for Healthcare Professionals
Solutions Platform for Healthhcare Professionals This document should not be distributed with hout Cegedim authorization – Copyright 2013 22
Slide 23: Payers Challenges
Payers Challenges This document should not be distributed with hout Cegedim authorization – Copyright 2013 23
Slide 24: Solutions Platform for Health Insurance Cie
Solutions Platform for Healthh Insurance Cie This document should not be distributed with hout Cegedim authorization – Copyright 2013 24
Slide 25: Global Information Services (GIS)
Global Information Services (GIS) Cegedim solution to demateria alize and archive all documents This document should not be distributed with hout Cegedim authorization – Copyright 2013 25
Slide 26: GIS, a Cegedim e-Business Comprehensive Offer
GIS, a Cegedim e-Business Comprehensive C Offer g and To Sign Archive all your To T dematerialize d t i li electronic and automate the documents with treatment of all probate value your invoices To transform all To exchange all your paper your electronic documents into documents (EDI) electronic d
Slide 27: Well-Diversified Blue-Chip Customer Base
Well-Diversified Blue-Chip Cuustomer Base 9 A network of 100,000 , online members 9 300 million exchanged electronic docu uments 9 1,000 large e-invoicing projects 9 Client references worldwide and in all sectors s This document should not be distributed with hout Cegedim authorization – Copyright
Slide 28: SEPA (Single Euro Payment Area)
SEPA (Single Euro Payment Area) 9 European p commission initiative to impplement new p pan European p payment p y instruments in Euros (transfers and dirrect debits) 9 Domestic payment instruments will com mpletely disappear in February 1st 2014, to the benefit of SEPA instruments 9 Responsibility
Slide 29: A Unique and Comprehensive Set of Solutions
A Unique and Comprehensivee Set of Solutions 9 Cegedim g designed g and implemented p a range g of solutions and services in order to facilitate and optimize migration to SEPA S direct debit Software suite MA€A (SEPA mandate manag gement and flows of associated payment) Available in license or
Slide 30: Where we are today?
Where we are today? 9 Cegedim g already y has numerous referen nces in License or SaaS mode Various contexts (Insurance, services, utilitie es, telco, real estate) and for pan-European collection management platforms 9 Market is in a state of ferment: Since Q4, numerous invitations to tender
Slide 31: Already some Blue-Chip Clients
Already some Blue-Ship Clients And 30+ French h Insurance Companies This document should not be distributed with hout Cegedim authorization – Copyright 2013 31
Slide 32: Well-Balanced and Diversified Revenue Mix
Well-Balanced and Diversifieed Revenue Mix 9 Revenue Breakdown as of September p 2012 Diversified revenue mix provide stable revenue base 9 Revenue Visibility 9 Low Customer Concentration Multi-Brand Strategy First client: 4.5% of Group revenue Strongg recurring g revenue model Topp 5 clie
Slide 33: Recent Achievements / 2012 Milestones
Recent Achievements / 2012 Milestones 9 Revenue growth of 1.4% 1 4% l-f-l in Q3 2012 2 9 Performance Improvement p Program g m ((P.I.P)) implemented p 9 Disposal of Pharmapost 9 Acquisition of ASP Line 9 Bank financial covenants reset 9 S&P’s rating improvement 9 Well positioned to take advantage
Slide 34: H1-2012 Revenue Overview
H1-2012 Revenue Overview This document should not be distributed with hout Cegedim authorization – Copyright 2013 34
Slide 35: H1-2012 Key figures
H1-2012 Key figures Impairment of Goodwill €115m G 5m Classical negative seasonal impact on WRC in H1 vs H2 This document should not be distributed with hout Cegedim authorization – Copyright 2013 35
Slide 36: H1-2012 Key Balance Sheet Figures
H1-2012 Key Balance Sheet Figures F Significant level Impairment of of shareholder Goodwill €115m G 5m equity it Substantial cash h available il bl This document should not be distributed with hout Cegedim authorization – Copyright 2013 36
Slide 37: H2-2012 Revenue Overview
H2-2012 Revenue Overview This document should not be distributed with hout Cegedim authorization – Copyright 2013 37
Slide 38: Recent Acquisition & Disposal Announcement
Recent Acquisition & Dispossal Announcement 9 Disposal p Leading French manufacturer of pharmaceu utical leaflets Disposal on April 30, 2012 2011 Revenue: €6,7m €6 7m 2011 EBITDA: €73k 9 Acquisition France’s fourth-largest g p publisher of p pharmac cist software Acquisition on July 20
Slide 39: Cash Situation on Average over 2008-2011
Cash Situation on Average ovver 2008-2011 This document should not be distributed with hout Cegedim authorization – Copyright 2013 39
Slide 40: Net Debt Situation
Net Debt Situation 9 Capital p Structure 9 Gross Debt by y Source of Financing g 9 Net Debt and Gearing This document should not be distributed with hout Cegedim authorization – Copyright 2013 40
Slide 41: Significant Liquidity Position
Significant Liquidity Positionn 9 Liquidity q y 9 Credit Rating g As of june 2012 Total Draw Availab ble 9 Standard & Poor’s Committed Facilites Revolving l Credit d Facilities l €80m €40m €40m B Stable outlook Cash & Cash Equivalent €55m ‐ €55m Confirmation on October 9, 2012 Group Other Committe
Slide 42: More Comfort on Financial Covenants
More Comfort on Financial Covenants C No breach of covenants at June 30, 2012 but need frrom more comfort Bank financial covenants reset in October 2012 gives s us significant headroom 9 New Bank Financial Covenant as of Octobeer 2012 9 Other Amendments No dividend while the Leverage Coverage Le
Slide 43: Strategy to Bond Refinancing: Move Step by Step
Strategy to Bond Refinancingg: Move Step by Step This document should not be distributed with hout Cegedim authorization – Copyright 2013 43
Slide 44: Disciplined Capital Deployment
Disciplined Capital Deploymeent 9 Capex p in million of € 2010 2011 H 2012 H1 Capitalization p of R&D 49% 50% 60% Maintenance Capex 19% 23% 25% Cegelease 15% 12% 15% Dividende 17% 15% 0% Total 100% 100% 100% Acquisition / Disposal 56.3 1.4 (4.3) Total Capex 138.0 94.9 37.0 9 R&D is a very importan
Slide 45: Business Seasonality
Business Seasonality 9 Traditionally higher sales on software at a the end of the year 9 Spending of remaining operating budget 9 More use of data and market research ini Q4 due to the reorganization of sales force organization of new campaign force, campaign, a annual reporting,… reporting This d
Slide 46: 2012 Outlook
2012 Outlook (1) 9 Despite p a satisfactory y performance p in Q3 Q 2012, the Group p prefers p to remain cautious 9 Th The target t t for f FY 2012 iis tto achieve hi a slightly sli htl increase i in i revenue combined bi d with a very slightly decrease of EBITDA A compare with 2011 (1) These pro
Slide 47: Cegedim Strives for Realistic Group Targets
Cegedim Strives for Realisticc Group Targets This document should not be distributed with hout Cegedim authorization – Copyright 2013 47
Slide 48: Mid-Term Financial Goals
Mid-Term Financial Goals Restore Profitability y 9 Restore profitability to 2009 level Increase Cash Cash-Flow Flow Generation 9 Increase cash conversion ratio Focus on Debt Reduction 9 Reach a leverage ratio of 2.0x Priority to Organic Growth 9 No acquisition in 2013 This document should
Slide 49: MI Touch
M Touch MI M. Franck k Perales (Cegedim RM)
Slide 50: Solutions Platform for Life Sciences Cie
Solutions Platform for Life Scciences Cie This document should not be distributed with hout Cegedim authorization – Copyright 2013 50
Slide 51: MI Touch
2 3 MI Touch 1 6 4 5 This document should not be distributed with hout Cegedim authorization – Copyright 2013 51
Slide 52: Docnet
Docnet Mrs Anne e Duclos (Cegedim RM)
Slide 53: Docnet
2 3 Docnet 1 6 4 5 Dedicated Website for Healthcare H Professionals This document should not be distributed with hout Cegedim authorization – Copyright 2013 53
Slide 54: Docnet
2 3 Docnet 1 6 4 5 9 Docnet is a sociall >75% of physicians expressed community dedica ated interest in Docnet (Cegedim Market for physicians Research) 9 Community memb bers Use of e-mail addresses strongly (Physicians only) are regulated. OneKey validatedd Cegedim is compliant with all privacy co
Slide 55: Docnet Features
2 3 Docnet Features Contact’s in nvitation 1 tto 1 messaging i or institution 1 Search any colleague 6 4 5 in healthcare organization Quick view on new product material, Suggested education, video, colleagues to add to multimedia my network presentation Useful apps for my activity or to recommend
Slide 56: Docnet Development
2 3 Docnet Development 1 6 4 5 In 2012, 4 countries launched in 2012 In 2013, 8 new countries (including Mexic co) + other countries to come 9 Deployment to support global groups for Pharma. 9 Companies digital communication: + Invite their Key doctors invitation on Docnet and communicate digita
Slide 57: Docnet's Clients
2 3 Docnet’s Clients 1 6 4 5 This document should not be distributed with hout Cegedim authorization – Copyright 2013 57
Slide 58: Product
2 3 Product 1 6 4 5 9 TURKISH PROMOTION http://youtube.googleapis.com/v/CFZ ZAyXxBZg8 This document should not be distributed with hout Cegedim authorization – Copyright 2013 58
Slide 59: What it Means for the Pharma Co
2 3 What it Means for the PharmaaCo 1 6 4 5 9 Brand informattion to their prescribers whatever the preferred channels c 9 Allowing to maanage in a more efficient way your digital marketin ng execution: More direct , fa ast and efficient way of communication Open/click ratees, Read time, Visits
Slide 60: What it Means for the Physician
2 3 What it Means for the Physiccian 1 6 4 5 9 Secured S Professiona f al Network Safety and secured acccess to healthcare envrionment Search for colleaguess or institutions of interest within healthcare Find and be found herre or abroad Contact a colleague 9 Personal inbox with relevant i
Slide 61: Cegedim Rx
Ce egedim Rx M. Simo on Driver (Cegedim Rx)
Slide 62: Solutions Platform for Healthcare Professionals
Solutions Platform for Healthhcare Professionals This document should not be distributed with hout Cegedim authorization – Copyright 2013 62
Slide 63: Cegedim Rx: Our Profile
2 3 Cegedim g Rx: Our Profile 1 6 4 5 9 The leading software and hardware pro ovider to pharmacy in the United Kingdom Alliance Boots Th Co-operative The C ti G Group Tesco Morrison's Superdrug Asda Sainsbury's Many Regional multiples Independents 9 Two software offerings g Pha
Slide 64: Vision
2 3 Vision 1 6 4 5 9 Our vision for the community p pharmacy market is to enable the transformation of medication m and clinical services using innovative tech hnology and partnerships to advance patient wellbeing, im mprove quality of care whilst reducing the cost burden This document should not
Slide 65: Our Current Offerings
2 3 Our Current Offerings 1 6 4 5 This document should not be distributed with hout Cegedim authorization – Copyright 2013 65
Slide 66: Cegedim Rx: The Customers
2 3 Cegedim Rx: The Customerss 1 6 4 5 9 Cegedim Rx has 6765 (52%) of 13,123 Re etail Pharmacies in UK Scotland 1215 (63%) Northern Ireland 707 (13%) Wales 510 (61%) England 10691 (50%) This document should not be distributed with hout Cegedim authorization – Copyright 2013 66
Slide 67: Cegedim Rx: The Customers
2 3 Cegedim Rx: The Customerss 1 6 4 5 9 High Street and Supermarket Pharmacie es Alliance Boots – 2430 pharmacies Sainsburys – 262 pharmacies Tesco – 352 pharmacies Asda – 219 pharmacies Morrisons – 117 pharma p acies Superdrug – 212 pharmacies The Co-operative Pharmacy – 770 pharma
Slide 68: Cegedim Rx: Business and IT Services
2 3 Cegedim Rx: Business and ITT Services 1 6 4 5 9 Pharmacy Business and IT Services des signed to simplify IT Product Development Deployment D l t Support Training Networking Infrastructure Hosting Application Development 9 "One Stop Shop" for all IT Needs This document should not
Slide 69: UK Market
2 3 UK Market 1 6 4 5 9 Chain Pharmacies corporately owned a are legally allowed in the UK 9 Pharmacy numbers in England have grrown by 12.2 % in past 10 years The greatest Th t t iincrease h has b been ffrom “100 hour”” pharmacies h i which hi h were iin th the main i ffrom grocery chains 9 Cha
Slide 70: UK Pharmacy Market
2 3 UK Pharmacy Market 1 6 4 5 9 UK Government has three Home nation n Health Services 9 Overall there is a massive drive to chan nge the NHS 9 Targeted savings of £20bn 9 Clinical commissioning groups (CCGs)) replace primary care trusts 9 Clinical commissioning groupsto take responsibility for £6
Slide 71: UK Pharmacy Landscape
2 3 UK Pharmacy Landscape 1 6 4 5 9 New and innovative medicines will continue to be developed p These include medicines which may require special handling (for example, temperature control) or administration to patients (for example, injjections by nurse). Accordingly, when aligned with an agei
Slide 72: UK Pharmacy Landscape
2 3 UK Pharmacy Landscape 1 6 4 5 9 Growth in pharmacies expected mainly in England in groups larger than 5 pharmacies. 9 Decline in small groups (less than 6 pha armacies) appears to be levelling out. 9 NI, Wales Pharmacy openings ‘stagnant’. This document should not be distributed with hout Cege
Slide 73: UK Pharmacy Landscape
2 3 UK Pharmacy Landscape 1 6 4 5 9 More healthcare services to be provide p ed in the community y Governments are seeking to provide more hea althcare services in the community in a cost effective way. Pharmacy is well placed to provide many of these services, such as medicine checkups, weight ma
Slide 74: United Kingdom Home Nation Programmes
2 3 United Kingdom Home Nation Programmes 1 6 4 5 Scope GPÆ Payment Claim Repeat Nomination / Pharmacy Dispensing Registration England g EPS R1 Acute and Chronic Rx’s Electronic Paper No No EPS R2 Acute and Chronic Rx’s Electronic Electronic Yes Yes S tl d Scotland eMAS Minor Ailments N/A Electron
Slide 75: Data at your fingertips 24/7
2 3 Data at your fingertips 24/7 1 6 4 5 9 Reduce dead stock 9 Identify excess stock 9 Reduce owings 9 Improve stock turn and efficiency 9 Demonstrate compliance 9 Vi View company growth h 9 Negotiate better deals This document should not be distributed with hout Cegedim authorization – Copyright
Slide 76: Head Office Reporting - Information Manager
2 3 Head Office Reporting - Inforrmation Manager 1 6 4 5 9 The reporting function for customer’s data d from Cegedim Rx 9 AWWeb b enabled bl d system, t so no hardware h d e outlay tl or desktop d kt supportt 9 Data protection due to a secure system m 9 Unique user name and passwords prov vide ind
Slide 77: We also provide Ad hoc data for Pharma Companies
We also provide Ad hoc data for Pharma Companies C
Slide 78: What does the future of UK pharmacy look like?
2 3 What does the future of UK pharmacy p look like? 1 6 4 5 9 Aspirationally More clinical services Pharmacist dispensing D i ili Domiciliary visits i it High Street Healthcare centres (HLP’s) 9 Pragmatically 4.7% average annual Rx growth in next 3 ye ears* Pressure on margins 20% i
Slide 79: Next Generation Strategic Intent
2 3 Next Generation Strategic Inttent 1 6 4 5 9 Our next pharmacy solution will build on o our experience in dispensing and patient record management to: Deliver a ‘patient centric’ centralised record allowing a authorised clinicians to access patients information regardless of the location to d
Slide 80: Aurora – UK Pharmacy Landscape
2 3 Aurora – UK Pharmacy Landsscape 1 6 4 5 9 An increasing proportion of prescriptio ons delivered electronically The Electronic Prescription Service enables the GP to send prescriptions electronically to the pharmacy of the patient’s choice making the e dispensing process safer and more convenie
Slide 81: UK Stakeholder Requirements
2 3 UK Stakeholder Requirementts 1 6 4 5 9 Centralised Stock Management, Fulfilm ment and Replenishment There is an increasing g demand for real tim me centralised stock management g to continue the drive for efficiencies within the supply cha ain. The future architecture must ensure that it can i
Slide 82: Cegedim Rx Strengths
2 3 Cegedim Rx 1 6 4 5 9 Strengths Legacy of customer centric innovation - allowing acquisition of new, larger customer groups. Strong customer relationships & deep und derstanding of the complexity of pharmacy. Proven track record dealing g with all custom mer g groups p – allowing g credib
Slide 83: Patient Portal
Patient Portal M. Oscar O Orri (Stacks)
Slide 84: Patient Portal: Introduction
2 3 Patient Portal: Introduction 1 6 4 5 9 Introduction New challe enges “W.H.O. “W H O warns governments ts that th t they th h d to had t adapt and cope with a sig gnificant increase in chronic disease in the 21th ce entury” “Europe should take mea asures with fewer resources to deal with mass s
Slide 85: Less resources + Demand
2 3 Patient Portal: Introduction 1 6 4 5 9 Healthcare organizations should begin n a reorganization process to cope with h new realities - Less resources + Demand The challenges = Doing more with less… 9 From ICT point of view, we see that Optimize to information systems had to suffer from a deep
Slide 86: Patient Portal: Introduction
2 3 Patient Portal: Introduction 1 6 4 5 9 Given this need, Stacks has started prrojects in chronic patient care. It leads to the following f projects and sub-projects: Stratification: System for grouping patients according a to policies Reengineering: g g Impact p of p policies in health in n
Slide 87: Patient Portal: What is it?
2 3 Patient Portal: What is it? 1 6 4 5 9 Autonomy: It is an interactive platform for all users who need to access healthcare services Particularlyy important p to improve p the degree g of autonomy in patient healthcare managemen nt 9 Responsibility: p y Taking advantage of new technologies
Slide 88: Patient Portal: General Aims
2 3 Patient Portal: General Aims 1 6 4 5 9 Encouraging communication between doctord and patient through an easy and secure cchannel y, using 9 Increasing patient health responsibility new technologies 9 Managing demand by controlling appointtments and alerting patient when necessary 9 Reducing bu
Slide 89: Patient Portal: Specific Aims
2 3 Patient Portal: Specific Aims 1 6 4 5 9 Standardizing, setting proceedings and a institutionalizing processes that are currently used by doctors as professio onal tools 9 Measuring and rewarding professional effforts Dissemination that help improve the system effectiven ness and efficiency 9 E
Slide 90: Portal Online: Example
2 3 Portal Online: Example 1 6 4 5 9 eHealth Patient Portal This document should not be distributed with hout Cegedim authorization – Copyright 2013 90
Slide 91: Online Portal: Example
2 3 Online Portal: Example 1 6 4 5 9 Access A as a patient ti t This document should not be distributed with hout Cegedim authorization – Copyright 2013 91
Slide 92: Clinical Station Reengineering
2 3 Clinical Station Reengineerinng 1 6 4 5 9 In clinical station, numerous virtual even nts are incorporated 9 Gradually even more will connect with Patient Portal, for be part of a single core 9 Examples: When a professional receives the result ofo a medical order, there is a point of interact
Slide 93: Cegedim Insurance
Ceged dim Insurance At the heart of health h data and payment flows M. Antoine Aiizpuru (Cegedim Insurance)
Slide 94: Solutions Platform for Health Insurance Cie
2 3 Solutions Platform for Healthh Insurance Cie 1 6 4 5 This document should not be distributed with hout Cegedim authorization – Copyright 2013 94
Slide 95: Personal Insurance: A Promising Market
2 3 Personal Insurance: A Promisingg Market 1 6 4 5 9 A market with g great potential p A growing market worth €32 billion (2010) noot to mention the €23 billion spent by households 93% of French citizens have supplemental health h insurance More than 700 market participants (insurers (insur
Slide 96: Cegedim Insurance: A Leading Position
2 3 Cegedim g Insurance: A Leadin ng g Position 1 6 4 5 9 40 million French p policyholders y (or ( 1 inn 2)) are managed g using g our solutions 9 300 market participants (insurers, mutu ual insurers and provident institutions) are clients 9 300 million health data and payment flo ows handled ann
Slide 97: Cegedim Insurance: A Leading Position
2 3 Cegedim Insurance: A Leadinng Position 1 6 4 5 HEALTHCARE OPERAT TORS INSURERS PROFESSIONALS COMPULSORY 9 Flow Managemeent HEALTH COVERAGE T h i l Cente Technical C ter MANAGEMENT Workstations FOR PRIVATE PRACTICE 9 Direct Paymeent by Insurers and Risk Manageme ent SUPPLEMENTARY HEALTH COVERAG
Slide 98: Cegedim Insurance: A Leading Position
2 3 Cegedim Insurance: A Leadinng Position 1 6 4 5 HEALTHCARE OPERATO ORS INSURERS PROFESSIONALS COMPULSORY 9 Flow Management HEALTH COVERAGE Technical Centerr MANAGEMENT Workstations FOR PRIVATE PRACTICE 9 Direct Paymennt by Insurers and Risk R Managemen nt SUPPLEMENTARY HEALTH COVERAGE MANAGEMEN
Slide 99: A Value Added, Complementary Product Offering
2 3 A Value Added, Complementaaryy Product Offeringg 1 6 4 5 SOFTWARE PUBLISHING BUSINESS SERVICES 9 Design, integration and supply of solutions in SaaS form 9 Third-party payment 9 Software S ft packages k f for compulsory l 9 Third Third-party party management outsourcing and supplemental insura
Slide 100: Sources of Growth
2 3 Sources of Growth 1 6 4 5 SOFTWARE PUBLISHING BUSINESS SERVICES 9 International 9 International 9 SaaS format allows us to supply clients 9 Online services accessible by health y solutions, regardless with turnkey g of size professional (pharmacy, hospital) 9 Partnerships for product enrichmen
Slide 101: Focus on: Online Services Linking Supplemental Health Insurers and Healthcare Professionals
Focus on: Online Services Linking Supplemental 1 2 3 6 4 Health Insurers and Healthcare e Professionals 5 9 Challenges: Pharmacist represent ¼ of insurers technicall expenditures Insurers are “blind blind payers” payers Few services associated with general-purposse third-party payer 9 Outloo
Slide 102: Conclusion
2 3 Conclusion 1 6 4 5 9 Changing g g technologies g and mentalities s Webservices, computerization of health proffessionals, mobile internet access 9 New products and services launched under u favorable economic conditions Pre ention self Prevention, self-medication, medication coaching coach
Slide 103: Keep in Touch With Cegedim
Keep in n Touch With Ce egedim
Slide 104: Cegedim and the Financial Market
Cegedim and the Financial Market M 9 Equity q y (1( year y p period)) 9 Bond ((1 year y p period)) 28 110 26 105 100 24 95 22 90 20 85 18 80 16 75 14 70 12 65 Dec‐11 Jun‐12 Dec‐12 Jan‐12 Apr‐12 Jul‐12 Oct‐12 Jan‐13 9 Equity Analyst Coverage 9 Credit Analyst Coverage CA Cheuvreux: Ch Michael Mi h
Slide 105: Keep in Touch with Cegedim
Keep in Touch with Cegedim This document should not be distributed with hout Cegedim authorization – Copyright 2013 105
Slide 106: Keep in Touch
Keep in Touch 9The Half-Year Report p 9The Corporate p This Document includes the Overview 2012 first half-year financial This document provides a statements and the quick qu c su summary ayo on Ceged Cegedim’ss management report. clients, business, key drivers, key figures. It is updated regularl
Slide 107: 2013 Financial Agenda
2013 Financial Agenda A month h earlier than last year This document should not be distributed with hout Cegedim authorization – Copyright 2013 107
Slide 108: An Award Winning Company (2011-2012)
An Award Winning Companyy (2011-2012) 9 Grand prix of Transparency “The prize have been awarded a in recognition for the best practices in regulated financial repo orting. It pay tribute to the listed French companies that have demonstrated d their ability to make use of the best financial commu
Slide 109: Solid Business and Financial Profile
Solid Business and Financial Profile This document should not be distributed with hout Cegedim authorization – Copyright 2013 109
Slide 110: Appendix
Appe endix
Slide 111: Strong and Stable Shareholder Base
Strong and Stable Shareholdder Base as of November 30, 2012 9 Shareholder Base 9 Board of Directors 9 Corporate Governance Compliance with the recommendation of the AFEP-MEDEF code Audit, Strategy, Nomination and p Compensation committees This document should not be distributed with hout Ceged
Slide 112: We welcome your questions and comments
We we elcome l your questions ti and d comments t Jan Eryyk UMIASTOWSKI Chi f In Chief Investment t t Officer Offi Head of Investor Relations Janeryk k.umiastowski@cegedim.com www.ceegedim.com/finance TEL: +3 33 (0) 1 49 09 33 36